MiNK Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
MiNK Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • MiNK Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$1.81M, a 64.7% increase year-over-year.
  • MiNK Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$13.8M, a 44.4% increase year-over-year.
  • MiNK Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$22.5M, a 19.8% increase from 2022.
  • MiNK Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$28M, a 7.35% increase from 2021.
  • MiNK Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$30.2M, a 86.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$13.8M -$1.81M +$3.31M +64.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$17.1M -$2.7M +$3.5M +56.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$20.6M -$3.81M +$1.87M +32.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$22.5M -$5.46M +$2.31M +29.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$24.8M -$5.12M +$1.22M +19.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$26M -$6.2M -$84.2K -1.38% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$25.9M -$5.69M +$2.09M +26.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$28M -$7.77M -$2.01M -34.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$26M -$6.33M +$7.94M +55.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$33.9M -$6.11M +$222K +3.51% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$34.1M -$7.78M -$3.93M -102% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$30.2M -$5.76M -$4.23M -276% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 -$26M -$14.3M -$8.22M -136% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$17.8M -$6.34M -$2.07M -48.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$15.7M -$3.85M +$546K +12.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$16.2M -$1.54M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-18
Q3 2020 -$6.04M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-29
Q2 2020 -$4.27M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-29
Q1 2020 -$4.39M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.